StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

Posted by Trevor Kearing on May 1st, 2024

Stock analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the stock.

Can-Fite BioPharma Stock Performance

Shares of NYSE CANF opened at $2.09 on Tuesday. The company has a market capitalization of $7.40 million, a price-to-earnings ratio of -1.17 and a beta of 1.53. The company has a 50 day simple moving average of $2.15 and a two-hundred day simple moving average of $2.10. Can-Fite BioPharma has a fifty-two week low of $1.76 and a fifty-two week high of $3.33.

Can-Fite BioPharma (NYSE:CANF – Get Free Report) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.20 million. On average, analysts forecast that Can-Fite BioPharma will post -0.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Schechter Investment Advisors LLC bought a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned 0.57% of Can-Fite BioPharma as of its most recent filing with the Securities & Exchange Commission. 21.00% of the stock is currently owned by institutional investors and hedge funds.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.